Previous studies have suggested that olive oil-based emulsion is safe and well tolerated in preterm infants, a showed efficacy and a good clinical and biological safety profile. The objective of this study was to assess the effects of a new olive-oil based lipid emulsion compared with the traditional lipid emulsions.

开始日期2012-07-01

申办/合作机构

上海交通大学

100 项与中/长链脂肪乳(C8～24Ve) 相关的临床结果

登录后查看更多信息

100 项与中/长链脂肪乳(C8～24Ve) 相关的转化医学

登录后查看更多信息

100 项与中/长链脂肪乳(C8～24Ve) 相关的专利（医药）

登录后查看更多信息

项与中/长链脂肪乳(C8～24Ve) 相关的文献（医药）

2015-01-01·BioMed Research International3区 · 生物学

Lipid Emulsion Attenuates Acetylcholine-Induced Relaxation in Isolated Rat Aorta

3区 · 生物学

ArticleOA

作者: Cho, Hyunhoo ; Yu, Jongsun ; Han, Jeong Yeol ; Lee, Soo Hee ; Baik, Jiseok ; Hong, Jeong-Min ; Ok, Seong-Ho ; Chung, Young-Kyun ; Lee, Heon Keun ; Park, Jungchul ; Sohn, Ju-Tae ; Shin, Il-Woo ; Lee, Youngju ; Choi, Mun-Jeoung

We investigated the effect of Lipofundin MCT/LCT and Intralipid on acetylcholine-induced nitric oxide- (NO-) mediated relaxation in rat aorta to determine which lipid emulsion (LE) is more potent in terms of inhibition of NO-induced relaxation. Dose-response curves of responses induced by acetylcholine, the calcium ionophore A23187, and sodium nitroprusside were generated using isolated rat aorta with or without LE. The effect of Lipofundin MCT/LCT on acetylcholine-induced endothelial nitric oxide synthase (eNOS) phosphorylation in human umbilical vein endothelial cells (HUVECs) was investigated using western blotting. Lipofundin MCT/LCT (0.1 and 0.2%) attenuated acetylcholine-induced relaxation in endothelium-intact aorta with or without tiron, whereas 0.2% Intralipid only inhibited relaxation. Lipofundin MCT/LCT inhibited relaxation induced by the calcium ionophore A23187 and sodium nitroprusside in endothelium-intact aorta, but Lipofundin MCT/LCT had no effect on sodium nitroprusside-induced relaxation in the endothelium-denuded aorta. Combined pretreatment withl-arginine plus Lipofundin MCT/LCT increased acetylcholine-induced maximal relaxation in endothelium-intact aorta compared with Lipofundin MCT/LCT alone.l-Arginine attenuated Lipofundin MCT/LCT-mediated inhibition of acetylcholine-induced eNOS phosphorylation in HUVECs. Taken together, Lipofundin MCT/LCT attenuated acetylcholine-induced NO-mediated relaxation via an inhibitory effect on the endothelium including eNOS, which is proximal to activation of guanylyl cyclase.

2005-11-01·The Kaohsiung Journal of Medical Sciences4区 · 医学

Efficacy of Medium‐chain Triglycerides Compared with Long‐chain Triglycerides in Total Parenteral Nutrition in Patients with Digestive Tract Cancer Undergoing Surgery

4区 · 医学

ArticleOA

作者: Chen, Fang‐Ming ; Sun, Li‐Chu ; Hsieh, Jan‐Sing ; Huang, Tsung‐Jen ; Wang, Jaw‐Yuan ; Juang, Rue‐Fen

The objectives of this prospective, randomized study were to evaluate the efficacy and tolerability of the short‐term use of medium‐chain triglyceride/long‐chain triglyceride (MCT/LCT) fat emulsions, and to compare the hematologic and biochemical effects of MCT/LCT fat emulsions with LCT fat emulsions in gastrointestinal (GI) tract cancer patients following surgery. Thirty patients with GI tract cancer requiring total parenteral nutrition (TPN) were equally randomized to receive MCT/LCT or LCT emulsions for 7 days. After 7 days, no sign of complications directly related to administration of fat emulsions was observed and there were no marked differences in anthropometry, length of hospital stay, and surgical complication rates between the two groups. However, MCT/LCT significantly improved plasma prealbumin concentration (p = 0.005). Changes in complements C3 and C4, total lymphocyte count, and immunoglobulins after TPN were not significantly different between the groups. Serum triglyceride and cholesterol levels remained constant. The serum insulin level in the MCT/LCT group was higher than in the LCT group (p = 0.048). Our data revealed that MCT/LCT fat emulsions significantly enhanced nutritional status in patients with GI tract cancer, indicated by higher prealbumin levels, which might be partially due to the higher circulating insulin levels in the MCT/LCT group.

2005-04-01·Current Drug Delivery4区 · 医学

Decrease in Fungizone™ Toxicity Induced by the Use of Lipofundin™ As a Dilutent: An In Vitro Study

4区 · 医学

Article

作者: De Araujo, Ivonete Batista ; Do Egito, E. Socrates Tabosa ; Soares, Luiz Alberto Lira ; De Medeiros, Tereza Maria Dantas ; Damasceno, Bolivar P. G. L.

The aim of this work was to develop an in vitro experimental protocol for the evaluation of toxicity and efficacy of an amphotericin B (AmB) micelle system, Fungizone, which was previously diluted with a lipid based emulsion for parenteral use, named Lipofundin LCT/MCT-20%. Two cell models were used for the experiments: Red Blood Cells (RBC) from human donnors and Candida tropicalis (Ct). These models were used to perform the toxicity and activity of the Fungizone/ Lipofundin admixture (AmB-LP) and the Fungizone (AmB-M) alone. While potassium (K+) and hemoglobin leakage from RBC were the parameters used to evaluate the acute and chronic toxicity, respectively, the efficacy of AmB-LP and AmB-M were assessed by K+ leakage or cell survival rate (CSR) from Ct. The results show that the toxicity of AmB-LP to RBC was concentration dependent concerning the K+ leakage; while at high concentrations, 5 and 50 mg x mL(-1), the leakage was 50.91 +/- 2.09% and 95.71 +/- 0.64%, respectively, at a concentration of 0.5 mg x mL(-1) this value was 17.16 +/- 1.57% and the value tended to zero for the lowest concentration studied, 0.05 mg x mL(-1). Surprisingly, AmB-LP induced very low hemoglobin leakage for all concentrations studied. At the highest concentration, 50 mg x mL(-1), this value was around 3%. When the cell model was Ct, the results changed completely. Not only high concentrations of AmB-LP, but also lower ones were able to induce a K+ permeability of around 100%. The CSR parameter showed an inverse correlation with the concentration; high values, between 50 and 5 mg x mL(-1), resulted in a CSR of around 8%. On the other hand, for lower concentration values, 0.05 and 0.5 mg x mL(-1), this one was around 80%. The same profile of activity against Ct was found for AmB-M. Only a small variation was found for the K+ leakage at 0.05 mg x mL(-1) that presented a value of 96.99 +/- 2.53%. However, AmB-M seemed to be much more toxic than AmB-LP. Its induction of hemoglobin leakage started at 0.5 mg x mL(-1) and reached the 100% at 5 mg x mL(-1). K+ leakage results were worse. The intermediate concentrations of study, 0.5 and 5 mg x mL(-1), presented a significant increase compared to AmB-LP. All together these results reveal that the activity of AmB is not only concentration dependent, but also depends on the drug carrier in which this compound was inserted. The AmB-LP preparation showed the same efficacy as AmB-M, but with a low toxicity. Therefore, AmB-LP presented a higher therapeutic index that permits the administration of high concentration of AmB without revealing side effects. However, the simple mixture of two complex pharmaceutical entities, as micelles and emulsions, should be analyzed carefully to assure that physicochemical stability is not reduced and thereby cause a different biodistribution in vivo.

项与中/长链脂肪乳(C8～24Ve) 相关的新闻（医药）

2023-12-20

·米内网

【市场】暴涨630%！独家降糖中成药申请保护

精彩内容12月19日，NMPA官网公示称，桑枝总生物碱片申请中药保护获得受理。该产品是一款口服降糖中药新药，为五和博澳药业的独家品种（含剂型独家，下同），2023年上半年在中国城市实体药店终端销售额增速超过630%。据统计，今年以来，已有49个品种申请中药保护获受理（含初保及续保）。来源：CDE官网桑枝总生物碱片由五和博澳药业开发，于2020年3月首次获NMPA批准上市，被誉为“近10年来首个获批上市的糖尿病中药新药”。其主要成分——桑枝总生物碱是以“桑枝”为原料，经提取、分离、纯化得到的多羟基生物碱有效组分，对α-葡萄糖苷酶具有极强的抑制活性。临床研究表明，无论单独使用还是用于二甲双胍控制不佳的联合治疗，桑枝总生物碱片均显示出良好的降糖化血红蛋白疗效，降低值达0.93%，疗效堪与化学药阿卡波糖相媲美，但副作用更小。得益于优异的临床疗效，该药自上市以来便进入市场快速放量期，2023年上半年在中国城市实体药店终端销售额首次突破1000万元，同比增速达630%，是糖尿病用中成药TOP3产品。近年来中国城市实体药店终端桑枝总生物碱片销售趋势（单位：万元）来源：米内网中国城市实体药店药品终端竞争格局米内网数据显示，五和博澳药业还在探索桑枝总生物碱片用于成人减重等方面，相关研究试验（受理号：CXZL2300054）于近日获批临床；另一款2.3类改良型新药紫杉醇中/长链脂肪乳注射液（胆固醇结合型）已进入Ⅰ期临床，拟用于乳腺癌、胃癌的一线和二线治疗。五和博澳药业在研产品情况来源：米内网中国申报进度（MED）数据库今年以来，NMPA至少发布了35则有关中药品种保护受理公示的通知，共涉及49个中药品种，其中以申请初保居多，占比接近七成。从厂家批文看，除了注射用血塞通（冻干）、红花逍遥片、追风透骨胶囊、注射用红花黄色素，其余品种均为独家品种。2023年至今受理的中药品种保护申请资料来源：米内网数据库、NMPA官网注：米内网《中国城市实体药店药品终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至12月20日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与中/长链脂肪乳(C8～24Ve) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00497289 (CTgov)	临床2期	早产儿疾病	48	Lipidem (MCT:LCT:FO / 5:4:1)	(遞淵願憲齋獵鏇選醖繭) = 顧糧淵膚艱鑰廠鏇窪淵衊築願顧艱遞醖顧築衊 (構簾襯襯壓蓋壓窪遞選, 夢窪糧夢觸積夢鏇製網 ~ 壓獵簾簾淵廠膚衊艱憲) 更多	-	2021-03-10
				LCT+Lipofundin MCT (MCT:LCT / 1:1)	(遞淵願憲齋獵鏇選醖繭) = 鬱襯獵繭夢憲襯壓範襯衊築願顧艱遞醖顧築衊 (構簾襯襯壓蓋壓窪遞選, 顧壓網醖醖積窪鏇鑰製 ~ 選顧襯壓齋膚壓淵網憲) 更多